Revolution Medicines starts phase 3 trial for pancreatic cancer drug

April 2, 2026 8:01 AM

Revolution Medicines Inc. has begun treating patients in a phase 3 clinical trial evaluating daraxonrasib as a first-line treatment for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found